Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - PLUS THERAPEUTICS, INC. | cytx-ex321_15.htm |
| EX-31.2 - EX-31.2 - PLUS THERAPEUTICS, INC. | cytx-ex312_7.htm |
| EX-31.1 - EX-31.1 - PLUS THERAPEUTICS, INC. | cytx-ex311_14.htm |
| EX-10.44 - EX-10.44 - PLUS THERAPEUTICS, INC. | cytx-ex1044_276.htm |
| EX-10.43 - EX-10.43 - PLUS THERAPEUTICS, INC. | cytx-ex1043_275.htm |
| EX-4.33 - EX-4.33 - PLUS THERAPEUTICS, INC. | cytx-ex433_277.htm |
| 10-K - 10-K - PLUS THERAPEUTICS, INC. | cytx-10k_20171231.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Cytori Therapeutics, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-215365 and 333-219967), Form S-3 (Nos. 333-153233, 333-159912, 333-192409, 333-200090, 333-195846, 333-216947 and 333-217988) and Form S-8 (Nos. 333-210211, 333-202858, 333-181764, 333-82074, and 333-122691) of Cytori Therapeutics, Inc. (the “Company”) of our report dated March 9, 2018, relating to the 2017 consolidated financial statements and financial statement schedule, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
March 9, 2018